Immunomedics, Inc. (NASDAQ:IMMU) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.13, Morningstar.com reports. The firm had revenue of $0.64 million during the quarter, compared to analyst estimates of $0.75 million. During the same period in the previous year, the firm earned ($0.17) earnings per share. The company’s quarterly revenue was down 31.2% on a year-over-year basis.

Immunomedics (NASDAQ:IMMU) opened at 7.78 on Thursday. Immunomedics has a 1-year low of $2.02 and a 1-year high of $9.51. The firm’s market capitalization is $852.72 million. The company’s 50-day moving average price is $8.53 and its 200 day moving average price is $6.88.

A number of equities research analysts have recently weighed in on IMMU shares. BidaskClub cut Immunomedics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Jefferies Group LLC set a $8.00 price objective on Immunomedics and gave the company a “buy” rating in a research note on Thursday, April 20th. Zacks Investment Research raised Immunomedics from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Monday, July 17th. ValuEngine raised Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Immunomedics in a research note on Monday, July 24th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $12.00.

ILLEGAL ACTIVITY WARNING: “Immunomedics, Inc. (IMMU) Releases Earnings Results, Misses Expectations By $0.13 EPS” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/17/immunomedics-inc-immu-releases-earnings-results-misses-expectations-by-0-13-eps.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of IMMU. Raymond James Financial Services Advisors Inc. raised its position in Immunomedics by 11.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 1,473 shares during the period. The Manufacturers Life Insurance Company raised its position in Immunomedics by 2.3% in the second quarter. The Manufacturers Life Insurance Company now owns 79,520 shares of the biopharmaceutical company’s stock valued at $702,000 after buying an additional 1,763 shares during the period. State Street Corp raised its position in Immunomedics by 37.2% in the second quarter. State Street Corp now owns 4,818,847 shares of the biopharmaceutical company’s stock valued at $42,549,000 after buying an additional 1,305,298 shares during the period. Gotham Asset Management LLC acquired a new position in Immunomedics during the second quarter valued at about $2,388,000. Finally, DAFNA Capital Management LLC raised its position in Immunomedics by 152.5% in the second quarter. DAFNA Capital Management LLC now owns 637,700 shares of the biopharmaceutical company’s stock valued at $5,631,000 after buying an additional 385,126 shares during the period. Hedge funds and other institutional investors own 63.39% of the company’s stock.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Earnings History for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.